[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intracranial-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intracranial-neoplasm":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100552549","fluoroethyltyrosine-for-the-evaluation-of-intracranial-neoplasm-100552549",false,"NCT06474533","Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm","Inclusion Criteria:\n\n* Presence or suspicion of intracranial neoplasm in two populations:\n\n  * Population 1: Participants after primary treatment (radiation therapy and\u002For surgery) with suspicion of recurrence on MRI.\n  * Three sub-populations will be considered:\n\n    * Recurrent metastatic lesions.\n    * Recurrent high-grade gliomas (Grades 3 and 4).\n    * Recurrent low-grade gliomas (Grade 2).\n  * Population 2: Participants prior to primary treatment with planned biopsy or surgical resection.\n* Age \\> 3 years.\n\nParticipants in other clinical trials will be eligible for this study including patients undergoing surgery guided by 5-aminolevulinic acid.\n\nExclusion Criteria:\n\n* Participants with known incompatibility to PET or Computerized tomography (CT)\u002Fmagnetic resonance imaging (MRI) scans.\n* Participants unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.\n\n  * Sedation or anesthesia can be used for participants who cannot tolerate the exam.","ALL","4 Years",{"count":18,"type":19},199,"ESTIMATED","OBSERVATIONAL","This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.",[23],"Intracranial Neoplasm",[25],"Imaging Studies","RECRUITING","2026-03-30",{"date":29,"type":30},"2026-04-03","ACTUAL",{"date":32,"type":30},"2024-06-21",{"date":34,"type":19},"2028-08-31",{"name":36,"class":37},"Thomas Hope","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":38},"100383857","hypofractionated-proton-therapy-for-benign-intracranial-brain-tumors-the-hippi-study-100383857","NCT04278118","Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study","HiPPI: A Phase 2 Trial of Hypofractionated Pencil Beam Scanning Proton Therapy for Benign Intracranial Tumors","HiPPI","Inclusion Criteria:\n\n* Pathologically or radiographically diagnosed benign intracranial or nerve sheath tumor, including meningiomas, pituitary adenomas, schwannomas. World Health Organization (WHO) grade 2-3 meningiomas are also allowed\n* Recommended to receive proton or photon fractionated radiation therapy\n* Signed informed consent\n\nExclusion Criteria:\n\n* Pregnant females are excluded. Female of child-bearing potential (FCBP) must have a negative serum or urine pregnancy test prior to starting therapy. FCBP must agree to use adequate contraception (at least one highly effective method and one additional method of birth control at the same time or complete abstinence) prior to study entry, for the duration of study. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.\n\n  * A female of childbearing potential (FCBP) is a sexually mature woman who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 12 consecutive months (if age \\>= 55 years); if the female subject is \\\u003C 55 years and she has been naturally postmenopausal for \\>= 1 year her reproductive status has to be verified by additional laboratory (lab) tests (\\\u003C 20 estradiol OR estradiol \\\u003C 40 with follicle stimulating hormone \\[FSH\\] \\> 40 in women not on estrogen replacement therapy)\n* Prior radiation therapy that would overlap with current target volume\n* Inability to undergo magnetic resonance imaging (MRI)","18 Years",{"count":49,"type":19},70,"INTERVENTIONAL",[52],"NA","This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells. A shorter duration of radiation treatment may avoid some of the delayed side effects of radiation while providing a more convenient treatment and reducing costs.",[55,56,57,23,58,59,60],"Grade I Meningioma","Grade II Meningioma","Grade III Meningioma","Nerve Sheath Neoplasm","Pituitary Gland Adenoma","Schwannoma","2026-02-12",{"date":63,"type":30},"2026-02-17",{"date":65,"type":30},"2020-02-18",{"date":67,"type":19},"2031-12-01",{"name":69,"class":37},"Emory University"]